<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152255</url>
  </required_header>
  <id_info>
    <org_study_id>6186-007</org_study_id>
    <secondary_id>2010_542</secondary_id>
    <nct_id>NCT01152255</nct_id>
  </id_info>
  <brief_title>MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)</brief_title>
  <official_title>A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6186 in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of MK6186 and the change from baseline
      in plasma HIV-1 RNA after seven consecutive days of dosing.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma HIV-1 RNA</measure>
    <time_frame>Baseline and Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MK6186 measured by number of clinical and laboratory adverse experiences</measure>
    <time_frame>through Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C(24 hour) of MK6186</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Panel A - MK6186 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK6186 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - MK6186 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK6186 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C - MK6186 &lt;=150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK6186 &lt;=150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D - MK6186 &lt;=150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK6186 &lt;=150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK6186</intervention_name>
    <description>Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose &lt;= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose &lt;= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)</description>
    <arm_group_label>Panel A - MK6186 40 mg</arm_group_label>
    <arm_group_label>Panel B - MK6186 150 mg</arm_group_label>
    <arm_group_label>Panel C - MK6186 &lt;=150 mg</arm_group_label>
    <arm_group_label>Panel D - MK6186 &lt;=150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo tablets taken orally for seven day</description>
    <arm_group_label>Panel A - Placebo</arm_group_label>
    <arm_group_label>Panel B - Placebo</arm_group_label>
    <arm_group_label>Panel C - Placebo</arm_group_label>
    <arm_group_label>Panel D - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Other than HIV infection, patient's baseline health is judged to be stable

          -  Patient is documented HIV-1 positive

          -  Patient has not received an investigational agent or licensed ART with in the past 30
             days

        Exclusion Criteria:

          -  Patient has a history of stroke, chronic seizures, or major neurological disease

          -  Patient has a history of cancer

          -  Patient has used any immune therapy agents or immunosuppressive therapy within the
             past month

          -  Patient requires or anticipates the use of any prescription or non-prescription drugs
             during the study

          -  Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or
             has positive Hepatitis B surface antigen

          -  Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or
             caffeine (greater than 6 servings per day)

          -  Patient is an excessive smoker (more than 10 cigarettes per day)

          -  Patient has had major surgery, donated blood or participated in another
             investigational study within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of HIV-1 Infection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

